Jaguar Health says pediatric intestinal failure trial data show crofelemer cuts parenteral support needs up to 48%

Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc.

JAGX

0.00
  • Jaguar Health highlighted additional data already presented at ESPGHAN 2026 on liquid oral crofelemer as an add-on therapy in pediatric intestinal failure.
  • Ongoing studies indicated patients reduced reliance on parenteral support over more than a year of dosing, with tolerability described as favorable.
  • The update supports continued development of crofelemer for rare conditions including microvillus inclusion disease and short bowel syndrome.
  • Jaguar outlined a plan to seek Breakthrough Therapy designation for microvillus inclusion disease, with an NDA filing targeted for mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606300900ACCESSWRNAPR_____1184345) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.